+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Optic Nerves Disorder Treatment Market by Treatment Type, Indication, Distribution Channel, and Geography: Forecast up to 2027

  • PDF Icon

    Report

  • 145 Pages
  • July 2023
  • Region: Global
  • IHR Insights
  • ID: 5850100
10% Free customization
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Optic Nerves are the cranial nerves which connect the retinal cells to the optic chiasm. In the retina photoreceptor cells are present which receive light and transmit it to the brain in the form of electric impulses through the optic nerves. Based on the nature and area of the injury, dysfunction or damage to the optic nerves might lead to visual loss. One can develop vision impairment in either one or both eyes. A key factor fueling the market growth is a rise in the lifestyle diseases such as diabetes, blood pressure, hypertension, etc. owing to the adoption of a inactive lifestyle unhealthy diet, dearth of physical activities, etc. which further increase the possibilities of multiple sclerosis resulting in the optic neuritis. Owing to this, there is a surge in the ratio of people requiring treatment for the disease. On the contrary, the adverse effects of using drugs for disorder treatment may limit the optic nerves disorder treatment market growth. The Optic Nerves Disorder Treatment Market is expected to rise at a rate of 4.5% CAGR by 2027.

Optic Nerves Disorder Treatment Market based on Treatment Type

  • Steroidal Therapy
  • Immunomodulators therapy
  • Others

Optic Nerves Disorder Treatment Market based on Indication

  • Glaucoma
  • Optic Neuritis
  • Others

Optic Nerves Disorder Treatment Market based on Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

Optic Nerves Disorder Treatment Market based on Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of World
The market based on treatment type is further segmented as Steroidal Therapy, Immunomodulators therapy and Others. The Immunomodulators therapy segment is likely to hold the highest share in the market. The highest share of the segment is due to the rise in the research and development activities for the manufacturing of immunomodulators for optic nerve disorder treatments coupled with the surge in number of key players has resulted increase in the launch of new drugs which further boost the optic nerves disorder treatment market growth.

Based on the indication the market is categorized as Glaucoma, Optic Neuritis and Others. The glaucoma segment held the significant share in the market owing to a surge in incidence of open angle glaucoma. In addition to this, the rise in number of approvals for drugs for the treatment of open angle glaucoma is projected to boost the optic nerves disorder treatment market growth.

Then further based on distribution channel, the market is bifurcated into Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers. The drug stores and retail pharmacies segment has the maximum share in the optic nerves disorder treatment market. Rising number of independent pharmacies and chains coupled with the availability of several rare disease medications in supermarkets and mass retailers are the reasons for segment growth.

In the regional market of optic nerves disorder treatment market, North America has acquired the major share in the market. Key factors propelling the growth of the optic nerves disorder treatment market are the substantial presence of leading pharmaceutical and biopharmaceutical companies in the North American region.

E-commerce (electronic commerce) has become a significant tool for small and large businesses worldwide, owing to the increase in preference of consumers for online shopping over conventional purchasing methods. This is ascribed to further supports for global market growth. The demand for optic nerve disorder treatment products is not only constrained to developed nations but is also being witnessed in developing nations, such as China, Brazil, and India, which boosts the growth of the global optic nerve disorder treatment market.

Prominent players operating in the market are Teva Pharmaceutical Industries Ltd, Bausch Health Companies, Inc., Santen Pharmaceutical Co. Ltd., AbbVie Inc., Novartis AG, Aerie Pharmaceuticals, Inc., Cipla Ltd, Merck & Co. Inc., mallinckrodt pharmaceuticals, and Pfizer, Inc.

As a result, there is significant scope for the optic nerve disorder treatment in the present scenario. This is due to the various factors such as advancements in the medical technology which have resulted in the development of new and more effective treatments for optic nerve disorder.

Key reasons to purchase the report:

  • This research segments the market completely and gives the nearest evaluations of the complete market size, along with that of the sub segments among major regions.
  • This report gives insightful analysis of the market and gives a comprehensive understanding of the market and its commercial landscape.
  • Provides the information about the market strategies which are being adopted by the competitors and leading organizations.
  • This report provides the perception of the future outlook and prospects for market analysis and forecast.

Table of Contents

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Treatment Type: Market Size & Analysis
5.1. Overview
5.2. Steroidal Therapy
5.3. Immunomodulators therapy
5.4. Others
6. Indication: Market Size & Analysis
6.1. Overview
6.2. Glaucoma
6.3. Optic Neuritis
6.4. Others
7. Distribution Channel: Market Size & Analysis
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug Stores and Retail Pharmacies
7.4. Online Providers
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. Teva Pharmaceutical Industries Ltd
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Bausch Health Companies, Inc.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Santen Pharmaceutical Co. Ltd.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. AbbVie Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Novartis AG
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Aerie Pharmaceuticals, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Cipla Ltd
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Merck & Co. Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. mallinckrodt pharmaceuticals
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Pfizer, Inc
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

Companies Mentioned

  • Teva Pharmaceutical Industries Ltd
  • Bausch Health Companies, Inc.
  • Santen Pharmaceutical Co. Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Aerie Pharmaceuticals, Inc.
  • Cipla Ltd
  • Merck & Co. Inc.
  • mallinckrodt pharmaceuticals
  • Pfizer, Inc